ICON Public Limited Company

ICON Public Limited Company Earnings Recaps

ICLR Health Care 2 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Nov 1, 2026

ICON shares rose 17.8% after the company reported record net business wins and sequential improvement in gross margin, adjusted EBITDA, and EPS. Management said Q3 results were in line with its expectations, while the transcript provides no market-consensus comparison.

Key takeaways
  • Net business wins reached a record $3.15 billion, up 51% year over year; net book-to-bill was 1.56x, the fourth consecutive quarter above 1.3x.
  • Gross margin improved 90 basis points sequentially. Adjusted EBITDA was $337 million, and adjusted EPS of $2.66 was up 4% from Q2.
  • Free cash flow was $300 million; ICON repurchased $400 million of shares and ended the quarter with $800 million in cash.
  • Commercial momentum included large-pharma strength, new and expanded midsized partnerships, and three preferred biotech partnerships.
  • Technology-enabled execution showed measurable gains: in-scope SDTM programming cycle times fell 28%, while study-startup throughput rose about 30% year to date.
Q1 2026 Jun 26, 2026

ICON’s shares rose 12.8% following earnings, driven by notably strong gross bookings, net business wins, and sustained momentum across key segments that outweighed modest revenue softness and margin pressure.

Key takeaways
  • Gross bookings hit $3.3 billion in Q1, up 22% year-over-year and consistent with the prior quarter’s strong performance.
  • Net business wins surged 42% year-over-year to $2.88 billion, resulting in a robust net book-to-bill ratio of 1.42x, signaling continued commercial strength.
  • Revenue came in at $2 billion, up 1% reported but down 1.9% on a constant currency basis, reflecting earlier-period demand challenges and cancellations.
  • Adjusted EBITDA margin was 15.6%, up slightly by 10 basis points sequentially despite revenue headwinds and mix shifts toward lower-margin functional services.
  • Strong demand momentum persisted across pharma full service, development solutions, and biotech segments, supported by improved RFP flow and win rates.